Next Generation Sequencing
Module Sequence Completed!
You have processed all queries for this module. Excellent performance!
Explore other knowledge matrices or review your progress.
Social Sharing!
Share your knowledge:
Suggest Favorite subject or vote for a trending one!
Having trouble? Here are some quick links:
No study tools available yet.
Time on task: 0 mins
No helpful links available yet.
You have processed all queries for this module. Excellent performance!
Explore other knowledge matrices or review your progress.
This statement is false. While a Prostate-Specific Antigen (PSA) level below 4.0 ng/mL was historically considered the upper limit of normal, it is not a definitive cutoff to rule out cancer. A significant proportion of men with prostate cancer (approximately 15-25%) have PSA levels within the so-called 'normal' range (<4.0 ng/mL). This is often referred to as 'PSA-negative' cancer. Conversely, many men with PSA levels above 4.0 ng/mL do not have cancer but have benign conditions like BPH or prostatitis. Therefore, PSA is a continuous risk factor, not a binary test. Other factors like PSA velocity (rate of rise), PSA density (PSA relative to prostate size), and free vs. total PSA ratio are used to refine risk assessment. A digital rectal exam is also crucial, as some aggressive cancers may not produce much PSA. Ultimately, the decision for biopsy is based on a combination of PSA, DRE findings, and patient risk factors, not on a single PSA cutoff.
Break down complex topics into smaller, manageable chunks for easier recall.
Zambia